Quick Answer
Mereo BioPharma Group plc reported Diluted EPS of $0.05 per share (loss) for fiscal year 2025.
Mereo BioPharma Group plc Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.05 | +16.7% |
| 2024 | -$0.06 | -50.0% |
| 2023 | -$0.04 | +42.9% |
| 2022 | -$0.07 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.01 | +50.0% | +50.0% |
| June 30, 2025 | -$0.02 | +0.0% | +0.0% |
| March 31, 2025 | -$0.02 | -100.0% | +0.0% |
| September 30, 2024 | -$0.02 | -100.0% | +0.0% |
| June 30, 2024 | -$0.02 | — | -100.0% |
| March 31, 2024 | -$0.01 | +50.0% | +0.0% |
| September 30, 2023 | -$0.01 | — | — |
| June 30, 2023 | $0.00 | — | +100.0% |
- Mereo BioPharma Group plc showed an increase of +16.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, Mereo BioPharma Group plc’s diluted eps has grown by 28.6% (from $0.07 per share (loss) to $0.05 per share (loss)).
- The most recent figure is from Mereo BioPharma Group plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: